Search for a clinical trial
Other search option(s)
35 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
BELGIUM
ANTWERPEN
ANTWERPEN-EDEGEM
An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease (Phase III) - BE
University and University Hospital of Antwerp - UZA
Department of pediatric metabolic diseases
CANADA
Nouvelle-Écosse
HALIFAX
Enzyme Replacement Therapy for Fabry Disease: A Model for the Integration of Rare Disease Therapeutics Into the Canadian Health Care System (Phase IV)
Dalhousie University
Department of Medicine, Division of Nephrology
CZECH REPUBLIC
Capital City Prague
PRAHA
FIELD : A Study of Two Fabrazyme (agalsidase beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (Phase IIIb) - CZ
First Faculty of Medicine and General Teaching Hospital
General Teaching Hospital and 1st Faculty of Medicine
FINLAND
Finland
TURKU
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease (Phase III)- FI
Turku University Hospital
Division of Medicine AC2
FRANCE
ILE-DE-FRANCE
GARCHES
A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease (Phase II) - Terminated -
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
FRANCE
ILE-DE-FRANCE
GARCHES
A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease (Phase II) - Terminated -
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
FRANCE
ILE-DE-FRANCE
GARCHES
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - FR
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
GERMANY
Bayern
OCHSENFURT
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - DE
Facharztpraxis für innere Medizin und Nephrologie
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
ATTRACT: A randomized, open-label study to compare the efficacy and safety of AT1001 and Enzyme Replacement Therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - DE
Institution: Information not provided - DE
ITALY
LOMBARDIA
RANICA
Evaluation of the long term efficacy of enzyme replacement therapy in Fabry disease (CLOSED)
Istituto di Ricerche Farmacologiche Mario Negri
Laboratorio Documentazione e Ricerca sulle Malattie Rare
NETHERLANDS
Noord-Holland
AMSTERDAM
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations (Phase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Endocrinologie en Metabolisme
NETHERLANDS
Noord-Holland
AMSTERDAM
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease
Amsterdam UMC, locatie AMC
Afdeling Endocrinologie en Metabolisme
NETHERLANDS
Noord-Holland
AMSTERDAM
FIELD : A Study of Two Fabrazyme (agalsidase beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (Phase IIIb) - NL
Amsterdam UMC, locatie AMC
Polikliniek Kindermetabole Ziekten
NORWAY
Vestlandet
BERGEN
FIELD : A Study of Two Fabrazyme (agalsidase beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (Phase IIIb) - NO
Haukeland University Hospital
Paediatric Department
POLAND
Warszawa
WARSAW
FIELD : A Study of Two Fabrazyme (agalsidase beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (Phase IIIb) - PL
Instytut "Pomnik-Centrum Zdrowia Dziecka"
Klinika Pediatrii, Zywienia i Chorob Metabolicznych
POLAND
Warszawa
WARSAW
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - PL
Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego
Klinika Kardiologii i Angiologii Interwencyjnej
SPAIN
Aragón
ZARAGOZA
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - ES (completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Aragón
ZARAGOZA
An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease (Phase III) - ES (Completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Aragón
ZARAGOZA
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients - ES (Completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Aragón
ZARAGOZA
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients (Phase I/II) - ES
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Cataluña
BARCELONA
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - ES (completed)
Fundació Puigvert
Servicio de Nefrología
SPAIN
Cataluña
BARCELONA
An Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in subjects with Fabry Disease (Phase III) - ES (Completed)
Fundació Puigvert
Servicio de Nefrología
UNITED KINGDOM
Greater London
LONDON
Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease (Phase II)
Royal Free Hospital
Department of Haematology
UNITED KINGDOM
Greater London
LONDON
PB-102-F01 - A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients - UK
Royal Free Hospital
Lysosomal Storage Disorders Unit
UNITED KINGDOM
Greater London
LONDON
FIELD : A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symptoms (Phase IIIb) - UK
Royal Free London Hospital
Lysosomal Disorders Unit
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT (phase III) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease (phase III) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
SALFORD
FAB-CL-204: A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease
Hope Hospital, University of Manchester
Department of Metabolic Disease
UNITED KINGDOM
Greater Manchester
SALFORD
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease (Phase IV) (Completed)
The Mark Holland Metabolic Unit
UNITED KINGDOM
Greater Manchester
SALFORD
An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease (phase III) - UK
The Mark Holland Metabolic Unit
Multinational clinical trial(s)
UNITED STATES
New Jersey
CRANBURY
A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease (Phase II) (coordination)
Amicus Therapeutics Inc.
UNITED STATES
New Jersey
CRANBURY
A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease (Phase II) (coordination)
Amicus Therapeutics Inc.
UNITED STATES
New Jersey
CRANBURY